Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.49, sa.1, ss.265-271, 2019 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 49 Sayı: 1
- Basım Tarihi: 2019
- Doi Numarası: 10.3906/sag-1706-194
- Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.265-271
- Anahtar Kelimeler: PD-1, PD-L2, multiple myeloma, acute leukemia, chronic lymphocytic leukemia
- Erciyes Üniversitesi Adresli: Hayır
Özet
Background/aim: PD-1 (programmed death-1) is an immune checkpoint receptor that modulates T-cell activity in peripheral tissues via interaction with its ligands, PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2). Tumor cells upregulate PD-L1 or PD-L2 to inhibit this T lymphocyte attack. Our goal was to determine the PD-1 and PD-L2 expression rates of various hematologic malignancies, and evaluate whether PD-1 and PD-L2 expressions have an impact on prognosis.